Literature DB >> 11837977

The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats.

M A Radwant1, H Y Aboul-Enein.   

Abstract

Poly(ethylcyanoacrylate) (PECA) nanospheres have been employed as biodegradable polymeric carriers for oral (po) delivery of insulin. The main goal of this investigation was to screen various absorption enhancers, which were used to protect insulin-loaded PECA, by following their in vivo performance after oral administrations to streptozotocin-induced diabetic rats. The nanospheres were prepared by polymerization in a continuous aqueous phase at pH 2.5 and in the presence of Pluronic 68 (0.5%). This polymerization technique was able to hold 85 +/- 7.5% of insulin added, 30 min after initiation of polymerization. The drug loading was evaluated by HPLC. Insulin absorption after oral administration was evaluated by its hypoglycemic effect. The addition of protease inhibitor to insulin-loaded PECA nanospheres significantly reduced the blood glucose level after po administrations. Capric acid (0.5%) showed the maximum reduction in blood glucose level (bG max = 34.4 +/- 4.1 mg%), while cholic acid (0.5%) showed the fastest reduction in blood glucose level (Tmax, G = 6.0 +/- 0.2 h) among the tested oral absorption enhancers. Insulin associated with PECA nanospheres retained its biological activity up to 12 days in 50% of the rats in the presence of glycyrrhizic acid (1%). The per cent pharmacological availabilities (PA%) were in the order of capric acid (0.5%) > glycyrrhizic acid (1%) > deoxycholic acid (0.5%) > hydroxypropyl-beta-cyclodextrin (HPbetaCD) (1%) > cholic acid (0.5%). There was no significant difference in the PA% between capric acid (0.5%), glycyrrhizic acid (1%) and deoxycholic acid (0.5%). Although sodium cholate (0.5%) showed the lowest increase in PA% (3.1 +/- 3.11%), its Tmax G was the shortest (6 +/- 0.2 h) among the tested absorption enhancers. The reduction in blood glucose levels was maintained < 200 mg/dL in the order of glycyrrhizic acid (166 +/- 56 h) > capric acid (72 h) >; deoxycholic acid (66 +/- 6 h) > no enhancer (64 +/- 16 h) > HPbetaCI) (31 +/- 17.5) > cholic acid (22 +/- 5.7 h) > aprotenin (20 +/- 3.5 h). Therefore, capric acid and glycyrrhizic acid could be successfully used as oral absorption enhancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11837977     DOI: 10.1080/02652040110081406

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  14 in total

1.  Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats.

Authors:  Mariko Morishita; Takahiro Goto; Koji Nakamura; Anthony M Lowman; Kozo Takayama; Nicholas A Peppas
Journal:  J Control Release       Date:  2005-12-02       Impact factor: 9.776

2.  Safe and effective permeation enhancers for oral drug delivery.

Authors:  Kathryn Whitehead; Natalie Karr; Samir Mitragotri
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

3.  Microneedles for drug delivery via the gastrointestinal tract.

Authors:  Giovanni Traverso; Carl M Schoellhammer; Avi Schroeder; Ruby Maa; Gregory Y Lauwers; Baris E Polat; Daniel G Anderson; Daniel Blankschtein; Robert Langer
Journal:  J Pharm Sci       Date:  2014-09-22       Impact factor: 3.534

Review 4.  Role and implications of nanodiagnostics in the changing trends of clinical diagnosis.

Authors:  Khalid Khalaf Alharbi; Yazeed A Al-Sheikh
Journal:  Saudi J Biol Sci       Date:  2013-11-19       Impact factor: 4.219

Review 5.  Lessons learned from the clinical development of oral peptides.

Authors:  Morten Asser Karsdal; Bente Juul Riis; Nozer Mehta; William Stern; Ehud Arbit; Claus Christiansen; Kim Henriksen
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

6.  Preparation and evaluation of oleoyl-carboxymethy-chitosan (OCMCS) nanoparticles as oral protein carriers.

Authors:  Ya Liu; Xiao Jie Cheng; Qi Feng Dang; Fang Kui Ma; Xi Guang Chen; Hyun Jin Park; Bum Keun Kim
Journal:  J Mater Sci Mater Med       Date:  2011-12-03       Impact factor: 3.896

7.  Novel mucosal insulin delivery systems based on fusogenic liposomes.

Authors:  Takahiro Goto; Mariko Morishita; Ken Nishimura; Mahito Nakanishi; Atsushi Kato; Jumpei Ehara; Kozo Takayama
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

8.  Development of acid-resistant alginate/trimethyl chitosan nanoparticles containing cationic β-cyclodextrin polymers for insulin oral delivery.

Authors:  Maryam Mansourpour; Reza Mahjub; Mohsen Amini; Seyed Naser Ostad; Elnaz Sadat Shamsa; Morteza Rafiee-Tehrani; Farid Abedin Dorkoosh
Journal:  AAPS PharmSciTech       Date:  2015-01-22       Impact factor: 3.246

9.  Complexation hydrogels for intestinal delivery of interferon beta and calcitonin.

Authors:  Noriyasu Kamei; Mariko Morishita; Hitomi Chiba; Nikhil J Kavimandan; Nicholas A Peppas; Kozo Takayama
Journal:  J Control Release       Date:  2008-11-27       Impact factor: 9.776

10.  Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.

Authors:  Mahasen A Radwan; Bushra T AlQuadeib; Lidija Šiller; Matthew C Wright; Benjamin Horrocks
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.